Ticker

Analyst Price Targets — CNTY

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
March 13, 2026 7:05 pmJeffrey StantialStifel Nicolaus$2.50$1.31StreetInsider Century Casinos (CNTY) PT Lowered to $2.50 at Stifel
March 13, 2026 1:15 pmJeffrey StantialStifel Nicolaus$3.00$1.38StreetInsider Stifel Reiterates Buy Rating on Century Casinos (CNTY) following Q4 report
October 21, 2025 11:28 amJeffrey StantialStifel Nicolaus$4.00$2.31StreetInsider Stifel Reiterates Century Casinos (CNTY) at Buy Rating on Constructive Outlook
July 18, 2025 8:47 amJordan BenderJMP Securities$3.00$2.55StreetInsider Citizens JMP Reiterates Market Outperform Rating on Century Casinos (CNTY)
November 5, 2024 7:56 amJordan BenderJMP Securities$5.00$4.03StreetInsider JMP Securities Upgrades Century Casinos (CNTY) to Market Outperform
August 8, 2022 9:38 amStifel Nicolaus$13.00$8.25Benzinga Stifel Maintains Buy on Century Casinos, Lowers Price Target to $13

Latest News for CNTY

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral…

GlobeNewsWire • Aug 12, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CNTY.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top